Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $61.80 USD
Change Today -0.30 / -0.48%
Volume 685.6K
ALKS On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

alkermes plc (ALKS) Key Developments

Alkermes plc Presents at UBS Global Healthcare Conference, May-18-2015 02:00 PM

Alkermes plc Presents at UBS Global Healthcare Conference, May-18-2015 02:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: James M. Frates, Chief Financial Officer, Senior Vice President and Treasurer, Rebecca J. Peterson, Senior Vice President of Corporate Communications.

Alkermes plc Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Reiterates Earnings Guidance for the Full Year of 2015

Alkermes plc reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s adjusted net income totaled $9.2 million or $0.06 per basic and diluted share, down from $16.2 million or $0.11 per basic and diluted share a year earlier. On a GAAP-basis, the net loss widened to $30.7 million or $0.21 per basic and diluted share from $24.4 million or $0.17 per basic and diluted share in the year-ago period. Revenues totaled $161.214 million, up 23.8% year-on-year compared to $130.212 million a year ago. Loss before income taxes was $30.147 million compared to $20.588 million a year ago. Capital expenditures were $10.710 million compared to $5.685 million a year ago. Free cash flow was $1.553 million compared to $10.466 million a year ago. For fiscal 2015, the company continues to expect a non-GAAP net loss of $0.37 to $0.50 per share on revenues of $600 million to $630 million.

Alkermes plc to Report Q1, 2015 Results on Apr 30, 2015

Alkermes plc announced that they will report Q1, 2015 results at 8:30 AM, US Eastern Standard Time on Apr 30, 2015

Alkermes plc, Q1 2015 Earnings Call, Apr 30, 2015

Alkermes plc, Q1 2015 Earnings Call, Apr 30, 2015

Alkermes Plans Phase 1 Clinical Study of Immuno-Oncology Drug Candidate in Third Quarter of 2015

Alkermes announced that based on preclinical data from studies of the company's selective effector cell activator (SECA) immuno-oncology drug candidate, RDB 1450, it plans to initiate a phase 1 clinical study in the third quarter of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALKS:US $61.80 USD -0.30

ALKS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Emergent Biosolutions Inc $31.08 USD -0.31
Impax Laboratories Inc $45.46 USD +0.35
Jazz Pharmaceuticals PLC $180.78 USD -0.06
Lupin Ltd 1,735 INR +26.10
Pacira Pharmaceuticals Inc/DE $77.58 USD -0.46
View Industry Companies
 

Industry Analysis

ALKS

Industry Average

Valuation ALKS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.2x
Price/Book 6.5x
Price/Cash Flow 377.8x
TEV/Sales 12.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.